Tables
- TABLE 1
An overview of selected trials investigating sequential or concurrent radio-chemotherapy
First author [ref.] Year Trial details Chemotherapy regimen Radiotherapy total dose Radiotherapy single dose 5-year OS Bradley [1] 2015 Phase III Carboplatin/paclitaxel (con) +/- cetuximab (cons) 60 Gy 2 Gy 57.6% (2-year OS) Carboplatin/paclitaxel (con) +/- cetuximab (cons) 74 Gy 2 Gy 44.6% (2-year OS) Oh [31] 2013 Phase III Cisplatin/paclitaxel (con/cons) 60–66 Gy 2–2.4 Gy Median OS 27.3 months Cisplatin/docetaxel (con/cons) 60–66 Gy 2–2.4 Gy Median OS 27.6 months Cisplatin/gemzitabine (con/cons) 60–66 Gy 2–2.4 Gy Median OS 16.5 months Curran [30] 2011 Phase III Cisplatin/vinblastin (con) 60 Gy 2 Gy 16.0% Cisplatin/vinblastin (seq) 60 Gy 2 Gy 10.0% Cisplatin/etoposide (con) 69.6 Gy 1,2 Gy twice a day 13.0% Segawa [32] 2010 Phase III MVP (con) 60 Gy 2 Gy 16.6% Docetaxel/cisplatin (con) 60 Gy 2 Gy 17.5% Yamamoto [33] 2010 Phase III MVP (con) 60 Gy 2 Gy 17.5% Carboplatin/irinotecan (con) 60 Gy 2 Gy 17.5% Carboplatin/paclitaxel (con) 60 Gy 2 Gy 19.5% Hanna [29] 2008 Phase III Cisplatin/etoposide (con) 59.4 Gy 1.8 Gy 26.1% (3-year OS) Cisplatin/etoposide (con) + docetaxel (cons) 59.4 Gy 1.8 Gy 27.1% (3-year OS) Gouda [28] 2006 Randomised Paclitaxel/carboplatin (con) 60 Gy 2 Gy 45% (2-year OS) Paclitaxel/carboplatin (ind/con) 60 Gy 2 Gy 40% (2-year OS) No chemotherapy 60 Gy 2 Gy 10% (2-year OS) Fournel [34] 2005 Phase III Cisplatin/etoposide (con) 66 Gy 2 Gy 21% (4-year OS) Cisplatin/vinorelbine (seq) 66 Gy 2 Gy 14% (4-year OS) Zatloukal [35] 2004 Randomised Cisplatin/vinorelbine (con) 60 Gy 2 Gy 18.6% (3-year OS) Cisplatin/vinorelbine (seq) 60 Gy 2 Gy 9.5% (3-year OS) Albain [36] 2002 Phase II Cisplatin/etoposide (con) 60 Gy 2 Gy 15.0% Furuse [37] 1999 Phase III MVP (con) 56 Gy 2 Gy 15.8% MVP (seq) 56 Gy 2 Gy 9.0% Lee [38] 1996 Phase II Cisplatin/etoposide (con) 69.6 Gy 1,2 Gy twice a day 35% (2-year OS) Jeremic [39] 1996 Randomised Carboplatin/etoposide (con) 69.6 Gy 1,2 Gy twice a day 23% (4-year OS) No chemotherapy 69.6 Gy 1,2 Gy twice a day 9% (4-year OS) Dillman [40] 1996 Phase III Cisplatine/vinblastine (con) 60 Gy 2 Gy 17% No chemotherapy 60 Gy 2 Gy 7% OS: overall survival; Con: concurrent; cons: consolidation; seq: sequential; MVP: mitomycin, vindesine, and cisplatin; ind: induction.
Vol 25 Issue 139
Table of Contents
Radio(chemo)therapy in locally advanced nonsmall cell lung cancer
